Bioventus (BVS) Stock Price, News & Analysis

Company Overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $7.28 to $7.49
• 50-Day Range: N/A
• 52-Week Range: $5.81 to $14.38
• Volume: 208,656 shs
• Average Volume: 403,621 shs
• Market Capitalization: $609.35 million
• P/E Ratio: 14.98
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Bioventus Stock Analysis - MarketRank™

Bioventus scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Bioventus.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bioventus is 14.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bioventus is 14.98, which means that it is trading at a less expensive P/E ratio than the Manufacturing sector average P/E ratio of about 21.91.

Price to Book Value per Share Ratio

Bioventus has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.96% of the float of Bioventus has been sold short.

Short Interest Ratio / Days to Cover

Bioventus has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Bioventus has recently increased by 13.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bioventus does not currently pay a dividend.

Dividend Growth

Bioventus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.96% of the float of Bioventus has been sold short.

Short Interest Ratio / Days to Cover

Bioventus has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Bioventus has recently increased by 13.21%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Bioventus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bioventus insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.00% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BVS Stock Analysis - Frequently Asked Questions

How have BVS shares performed this year?

Bioventus' stock was trading at $6.26 at the beginning of 2025. Since then, BVS shares have increased by 17.3% and is now trading at $7.34.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NASDAQ:BVS) issued its earnings results on Wednesday, August, 6th. The company reported $0.21 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. Bioventus had a negative net margin of 0.03% and a positive trailing twelve-month return on equity of 23.04%.

When did Bioventus IPO?

Bioventus (BVS) raised $126 million in an initial public offering (IPO) on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity served as the underwriters for the IPO.

How do I buy shares of Bioventus?

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BVS
• Previous Symbol: NASDAQ:BVS
• CIK: 1665988
• Web: N/A
• Phone: (919) 474-6700
• Fax: N/A
• Employees: 1,200
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 14.98
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.54 million
• Net Margins: -0.03%
• Pretax Margin: 0.85%
• Return on Equity: 23.04%
• Return on Assets: 6.04%

Debt

• Debt-to-Equity Ratio: 1.48
• Current Ratio: 1.48
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $573.28 million
• Price / Sales: 1.06
• Cash Flow: $1.05 per share
• Price / Cash Flow: 7.00
• Book Value: $2.43 per share
• Price / Book: 3.02

Miscellaneous

• Outstanding Shares: 82,680,000
• Free Float: 55,395,000
• Market Cap: $606.87 million
• Optionable: N/A
• Beta: 0.83